Clinical trials: Squamous Non-Small Cell Lung Cancer (NSCLC)
Squamous-cell Non-small Cell Lung Cancer
Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
A recent investigation showed that a substantial proportion of patients with SQCLC (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA) and are potentially sensitive to…
- Trial name
- NCT03762122
- Testing
- Rogaratinib
- Where
- 11 sites in Switzerland
- Volunteers
- 15 people
- Sponsor
- Swiss Cancer Institute
Non-small-cell Lung Cancer
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
The goal of this clinical research study is to compare 2 types of radiotherapy, stereotactic body photon radiotherapy (SBRT) and stereotactic body proton radiotherapy (SBPT).
- Trial name
- NCT01511081
- Testing
- SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small-Cell Lung Cancer
Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC
This study aims to investigate the efficacy and safety of immuno-chemotherapy in combination of cryoablation as the first-line treatment of advanced NSCLC
- Trial name
- NCT06483009
- Testing
- Cryoablation
- Volunteers
- 20 people
- Sponsor
- Shanghai Chest Hospital
NSCLC (Non-small Cell Lung Cancer)
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in First-Line ALK (Anaplastic Lymphoma Kinase)…
- Trial name
- NCT01639001
- Testing
- Crizotinib, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 207 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor…
- Trial name
- NCT05882734
- Testing
- M1774, Cemiplimab
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 61 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lung Neoplasm
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the…
- Trial name
- NCT06780098
- Testing
- R-DXD, I-DXD, Docetaxel
- Where
- 46 sites in United States, Chile and 9 more
- Volunteers
- 144 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
This study is a single-arm, prospective, multi-center clinical trial. designed to evaluate patients with stage IV inability to receive or refuse chemotherapy.Efficacy and safety of first-line treatment with Camrelizumab and Endo…
- Trial name
- NCT04303130
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
- Conditions
- Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer
- Trial name
- NCT01045421
- Testing
- MLN8237 (Alisertib)
- Where
- 2 sites in United States
- Volunteers
- 273 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
The goals of this prospective, observational cohort study are to determine the feasibility of implementing paclitaxel therapeutic drug monitoring for cancer patients and explore the relationship between paclitaxel drug exposure…
- Conditions
- Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma
- Trial name
- NCT03987555
- Testing
- Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer
A Study of Prevalence of EGFR Mutations in Participants With NSCLC
This is a non-interventional, local, multicenter, cross-sectional study to determine the prevalence of epidermal growth factor receptor (EGFR) mutations in participants diagnosed with non-squamous non-small cell lung cancer…
- Trial name
- NCT02695849
- Where
- 2 sites in Jordan
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Metastatic Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no…
- Trial name
- NCT05555732
- Testing
- Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 1,170 people
- Sponsor
- Daiichi Sankyo
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
The primary objective of this trial is to demonstrate pharmacokinetic (PK) similarity of ABP 234 compared with the pembrolizumab reference product (Keytruda®).
- Trial name
- NCT06311721
- Testing
- ABP 234, Pembrolizumab (US), Pembrolizumab (EU)
- Where
- 218 sites in United States, Argentina and 21 more
- Volunteers
- 315 people
- Sponsor
- Amgen
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028938
- Testing
- epoetin alfa, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Squamous Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC).
- Trial name
- INTerpath-13 (NCT07221474)
- Testing
- Intismeran Autogene, Pembrolizumab, Carboplatin
- Where
- 55 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Cutaneous Melanoma
RTX-224 Monotherapy in Patients With Solid Tumors
This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT05219578
- Testing
- RTX-224
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Rubius Therapeutics
Carcinoma, Non-Small-Cell Lung
Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
The purpose of this multicenter randomized study is to compare the effectiveness and safety of erlotinib and pemetrexed in the maintenance treatment of patients with advanced non-squamous non-small cell lung cancer (NSCLC)
- Trial name
- NCT03460678
- Testing
- Pemetrexed, Erlotinib
- Where
- 2 sites in Jordan, Lebanon
- Volunteers
- 9 people
- Sponsor
- Hikma Pharmaceuticals LLC
NSCLC Stage IV
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced Osimertinib-resistant non-squamous non-small cell lung…
- Trial name
- PCA (NCT04136535)
- Testing
- Pemetrexed, Carboplatin, Anlotinib
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung
Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.
At present, the treatment of non-squamous cell lung cancer is based on chemotherapy with platinum eventually associated with bevacizumab. A new treatment begins at progression.
- Trial name
- BUCiL (NCT01705184)
- Testing
- Cisplatin, Bevacizumab, Pemetrexed
- Where
- 12 sites in France
- Volunteers
- 120 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
NSCLC (Non-small Cell Lung Cancer), HNSCC
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
- Trial name
- NCT07814248
- Testing
- TS-104
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- TwoStep Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.